Latest Breaking News On - Maria palasis - Page 1 : comparemela.com

Lyra Therapeutics Announces Cost-Cutting Measures to

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

WATERTOWN, Mass., May 21, 2024 Lyra Therapeutics, Inc. , today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in.

Lyra Therapeutics Reports Topline Results from Phase 3

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE.

Chronic Rhinosinusitis Trial Evaluating Sinonasal Implant Misses Primary Endpoint

The ENLIGHTEN 1 study was a randomized, blinded, sham-controlled trial evaluated the efficacy and safety of LYR-210, a bioabsorbable nasal implant.

Around the house: NFL team Buffalo Bills dismisses GC and names interim, UK fusion energy pioneer hires former Rolls Royce counsel

Around the house: NFL team Buffalo Bills sacks GC and names interim, UK fusion energy pioneer hires former Rolls Royce counsel